Physician profile
Eric Shore
NPI 1932203494
$34,658.59
in general payments reported to CMS, 2019-2025
35 companies · $2,278 in 2025
The $2,278 reported for 2025 was more than what 78% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,287 · 2020: $10K · 2021: $2,416 · 2022: $11K · 2023: $4,001 · 2024: $1,983 · 2025: $2,278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,979 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,150 · Education: $100 · Travel and Lodging: $32.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,978.57 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,150.00 |
| Education | $100.34 |
| Travel and Lodging | $32.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $23,882.65 | 2019-2025 | Breztri, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $5,319.06 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $627.74 | 2019-2024 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Actelion Pharmaceuticals US, INC. | $457.10 | 2019-2025 | Opsumit, Uptravi, Opsynvi |
| Insmed, INC. | $438.46 | 2019-2025 | Arikayce, Brinsupri |
| Novartis Pharmaceuticals Corporation | $395.45 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $357.64 | 2021-2025 | Glassia, Cuvitru |
| Regeneron Healthcare Solutions, INC. | $316.45 | 2019-2025 | Dupixent |
| Mylan Specialty L.P. | $306.70 | 2019-2024 | Yupelri |
| Genentech USA, INC. | $305.17 | 2019-2023 | Xolair |
| Sunovion Pharmaceuticals INC. | $213.20 | 2019-2021 | |
| Amgen INC. | $182.70 | 2021-2025 | Tezspire |
| Verona Pharma, INC. | $181.84 | 2025 | Ohtuvayre |
| Genzyme Corporation | $174.77 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $168.57 | 2019-2024 | Xywav |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $160.84 | 2020-2024 | Acthar |
| Bayer Healthcare Pharmaceuticals INC. | $137.74 | 2019 | |
| Covis Pharma Gmbh | $123.41 | 2021-2022 | |
| Circassia INC. | $117.71 | 2019 | |
| Advanced Respiratory, INC | $102.20 | 2019-2021 | |
| Electromed, INC. | $91.67 | 2022-2025 | Smartvest |
| Baxter Healthcare | $79.27 | 2022-2025 | |
| Grifols USA, LLC | $77.98 | 2019-2023 | Prolastin-C Liquid |
| Philips North America LLC | $65.05 | 2019-2025 | Vest Therapy Und |
| Viatris Specialty LLC | $63.72 | 2025 | Yupelri |
| Merck Sharp & Dohme LLC | $52.67 | 2019 | |
| Mallinckrodt Enterprises LLC | $44.90 | 2019 | |
| Shire North American Group INC | $42.56 | 2019 | |
| Harmony Biosciences LLC | $35.90 | 2023 | Wakix |
| Abbvie INC. | $34.77 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $34.13 | 2019 | |
| Lilly USA, LLC | $23.67 | 2025 | Zepbound, Mounjaro |
| La Jolla Pharmaceutical Company | $17.92 | 2019 | |
| Inogen, INC. | $17.57 | 2025 | |
| Janssen Biotech, INC. | $7.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Shore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.